| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 619.99 | 775.1% |
| Total Income | 625.63 | 763.0% |
| Expenditure | 549.03 | 801.7% |
| PBT | 76.60 | 559.8% |
| Net Profit | 58.20 | 541.5% |
| OPM | 16.15% | 1.60pp |
| NPM | 9.30% | 3.21pp |
| EPS | 1.29 | 35.5% |
Marksans Pharma Ltd. Announces Q1 2025 Financial Results with 11.74% Increase in Revenue
12 Aug 2025 · 12 Aug 2025, 01:20 pm
Summary
Marksans Pharma Ltd. has announced its Q1 2025 financial results with a significant increase in revenue. The company's revenue for the quarter ended June 30, 2025, stands at INR 3,197.34 million, marking an increase of 11.74% from the same period last year. The company's profitability, margins, and other key financial indicators are detailed in the financial statements.
Key Highlights
- 1
Q1 2025 revenue stands at INR 3,197.34 million, marking an increase of 11.74% from the same period last year
- 2
Profitability, margins, and other key financial indicators are detailed in the financial statements
- 3
The company's financial statements have been reviewed by M/s. MSKA & Associates, Chartered Accountants
Management Comments
Name not provided
No management comments are provided in the document.
Informational and educational content only. Not investment advice.